Skip to content

N-acetyl cysteine is associated with dopaminergic enhancement in Parkinson’s disease

N-acetyl cysteine is associated with dopaminergic enhancement in Parkinson’s disease

This study investigated the biological and clinical effects of N-acetyl-cysteine (NAC), the prodrug to L-cysteine, a precursor of the natural biological antioxidant glutathione, in patients with Parkinson’s disease (PD). Forty-two patients with PD were randomized to receive either weekly intravenous infusions of NAC (50 mg/kg) plus oral doses (500 mg twice daily) for three months or standard treatment only.

Participants received pre- and postbrain imaging with ioflupane (DaTscan) to measure dopamine transporter (DAT) binding. Significantly increased DAT binding in the caudate and putamen (mean increase from 3.4% to 8.3%) and significant improvement in PD symptoms (P < 0.0001) were observed in the NAC group compared with controls (P < 0.05).

The results suggest that NAC may positively affect the dopaminergic system in patients with PD, with corresponding beneficial clinical effects.

Clin Pharmacol Ther.: N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson’s Disease

Powered by BetterDocs

This site is still under development. Feel free to look around and don't hesitate to give us feedback, you'll find a form at the end of each page.

Nevertheless, we activate a few cookies, and these cookies could change due to the fact. that it's a development-site.

Bye bye booze needs cookies, too. However, we try only to activate as few as possible technically necessary cookies so that your visit to this site cannot be tracked as far as possible by third parties.


However, we do need a few - e.g. to display this legal notice or to care for that you do not have to log in again for each page or see this popup again for each page.


As soon as you click on an external link or video, however, cookies may be set by the operators of these sites, which we cannot influence. Learn more on our privacy page.